Leaps by Bayer

Breaking Through Impossible

What does it take to solve some of the greatest challenges of our time in health and agriculture?

Leaps by Bayer is the strategic investment unit of Bayer. By accelerating transformative biotechnologies, they aim to shift key paradigms in life science, bringing Bayer’s mission 'Health for All, Hunger for none' closer to reality.

At the heart of Leaps by Bayer’s mission are ten ambitious goals –  the “10 Leaps” –  that form the foundation of its investment strategy.

In health, Leaps pursues technologies that could set new standards in medical care, moving from treating symptoms to curing or preventing diseases. In agriculture, they drive innovations that could nourish a growing population while restoring the planet.

The 10 Leaps

  1. Cure genetic diseases
  2. Provide sustainable organ & tissue replacement
  3. Reduce environmental impact of agriculture
  4. Prevent and cure cancer
  5. Protect brain and mind
  6. Reverse autoimmune diseases and chronic inflammation
  7. Provide next generation healthy crops
  8. Develop sustainable protein supply
  9. Prevent crop and food loss
  10. Transform health with data
     

To achieve the impossible, teamwork is essential. In Chapter III – Leap Forward, Leaps by Bayer brings together leading figures from science and sports to embark on a journey into the future. Their achievements show how collaboration can pave the way toward tomorrow.

Collaborating with the most visionary founders in the industry

 


Leaps partners with some of the brightest minds in biotechnology, agriculture, and healthcare. They invest in established companies or co-found new ventures with partners, providing significant and sustained investment, enabling them to focus on the long-term delivery of their disruptive technology. 

Their portfolio companies stay autonomous, supported through “active incubation,” where their experienced team provides resources and helps guide their strategic direction.

Since 2015, Leaps has invested over $2.1 billion in more than 65 companies working on disruptive innovations.

COR-OTH-CH-0048-1 2411